Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Congenital Adrenal Hyperplasia Market from 2024 to 2025?
In recent years, the market size for congenital adrenal hyperplasia has experienced robust growth. It is projected to expand from $0.47 billion in 2024 to $0.50 billion in 2025, marking a compound annual growth rate (CAGR) of 7.3%. The growth during the historical period can be attributed to factors like a surge in the incidence of congenital adrenal hyperplasia, increased uptake of corticosteroid therapies, an upward trend in healthcare spending, a heightened emphasis on pediatric care, and the expansion of government initiatives and reimbursement policies.
What Is the Projected Market Size of the Congenital Adrenal Hyperplasia Market?
In the upcoming years, the congenital adrenal hyperplasia market is projected to experience robust growth. It is estimated to expand to $0.66 billion by the year 2029 with a compound annual growth rate (CAGR) of 7.1%. The forecasted growth can be attributed to factors such as rising demand for individualized medicine, increase in genetic disorders, enhanced research on congenital adrenal hyperplasia treatments, an upsurge in healthcare investments, and a growing application of telemedicine in managing congenital adrenal hyperplasia. Expected trends over the forecast period include improvements in healthcare infrastructure, progress in molecular diagnostics, innovation in enzyme replacement therapies, and the formulation of long-acting corticosteroids, alongside advances in genetic screening processes.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21157&type=smp
Who are the Major Competitors in the Congenital Adrenal Hyperplasia Market Outlook?
Major companies operating in the congenital adrenal hyperplasia market are Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Eton Pharmaceuticals Inc, Teva Pharmaceutical Industries, Macleods Pharmaceuticals, H. Lundbeck A/S, Neurocrine Biosciences Inc., BridgeBio Pharma Inc, Regenxbio Inc., Millendo Therapeutics Inc., Applied Therapeutics, Inc., OMass Therapeutics Limited, ViennaLab Diagnostics GmbH, EffRx Pharmaceuticals SA, Adrenas Therapeutics Inc, HBM Alpha Therapeutics, Spruce Biosciences Inc., Crinetics Pharmaceuticals Inc.
What Is Fueling Growth in the Congenital Adrenal Hyperplasia Market?
An increasing demand for gene therapy is projected to fuel the expansion of the congenital adrenal hyperplasia market. Gene therapy is a medical procedure that involves altering or manipulating an individual’s genes as a means to treat or stave off disease. This growing demand can be credited to progress in genetic research and biotechnology, enabling more accurate and focused treatments for genetic conditions, cancers, and various chronic ailments. The disorder of congenital adrenal hyperplasia (CAH), which is triggered by gene mutations that impact adrenal hormone production, is a key area of interest in gene therapy. This offers the prospects for targeted genetic interventions to repair the root genetic flaws and re-establish regular hormone function. For example, as per the American Society of Gene and Cell Therapy (ASGCT) in April 2024, out of the 1,023 gene therapies being developed for rare ailments, eight of the top 10 were related to oncology. The second quarter of 2024 witnessed the start of 76 new gene therapy trials, showing a 25% rise from the prior quarter. Hence, the mounting demand for gene therapy is propelling growth in the congenital adrenal hyperplasia market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21157&type=smp
Which Congenital Adrenal Hyperplasia Market Segments Are Growing the Fastest?
The congenital adrenal hyperplasia market covered in this report is segmented –
1) By Type: Classic Congenital Adrenal Hyperplasia, Non-Classic Congenital Adrenal Hyperplasia
2) By Treatment And Diagnosis: Diagnosis, Treatment
3) By End-Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research Institutes
Subsegments:
1) By Classic Congenital Adrenal Hyperplasia: Salt-Wasting Classic Congenital Adrenal Hyperplasia, Simple Virilizing Classic Congenital Adrenal Hyperplasia
2) By Non-Classic Congenital Adrenal Hyperplasia: Late-Onset Non-Classic Congenital Adrenal Hyperplasia, Mild Non-Classic Congenital Adrenal Hyperplasia
Which Industry Trends Are Shaping the Future of the Congenital Adrenal Hyperplasia Market?
In the congenital adrenal hyperplasia market, key players are concentrating on the creation of advanced treatments such as CRF1 receptor antagonists. This treatment aims to control cortisol production and decrease excessive adrenal androgen. The CRF1 receptor antagonist is a type of medication that restrains the corticotropin-releasing factor 1 (CRF1) receptor to manage the body’s response to stress and curb overproduction of adrenal androgen persistent in congenital adrenal hyperplasia conditions. For example, Neurocrine Biosciences, Inc., a biopharmaceutical firm based in the US, gained FDA authorization for crenessity (crinecerfont) in December 2024. It is the first innovative treatment for congenital adrenal hyperplasia (CAH) in seven decades. This new drug serves as a specific antagonist of corticotropin-releasing factor type 1 receptors, aiding in the moderation of high ACTH levels and adrenal androgens, enabling a decrease in glucocorticoid dosages. The approval came on the bases of the CAHtalyst Phase 3 trials, which demonstrated significant effectiveness in reducing androgen levels. Crenessity is anticipated to be available shortly, which signifies a significant leap in CAH treatment.
Access The Full Report Here:
Which Countries Are Leading the Congenital Adrenal Hyperplasia Market?
North America was the largest region in the congenital adrenal hyperplasia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congenital adrenal hyperplasia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21157
This Report Delivers Insight On:
1. How big is the congenital adrenal hyperplasia market, and how is it changing globally?
2. Who are the major companies in the congenital adrenal hyperplasia market, and how are they performing?
3. What are the key opportunities and risks in the congenital adrenal hyperplasia market right now?
4. Which products or customer segments are growing the most in the congenital adrenal hyperplasia market?
5. What factors are helping or slowing down the growth of the congenital adrenal hyperplasia market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model